Checkpoint Therapeutics Inc expected to post a loss of $1.31 a share - Earnings Preview

Checkpoint Therapeutics

24/03/2023 12:15

* Checkpoint Therapeutics Inc  CKPT.OQ   CKPT.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 27 (estimated). 
    * The Waltham Massachusetts-based  company is expected to
report 
a 100.0% increase in revenue to $32 thousand from $16 thousand a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Checkpoint
Therapeutics
Inc is for a loss of $1.31 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $54​, above​ its last closing price
of $3.59. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.47       -1.47      -1.20     Beat    18.2
 Jun. 30 2022  -1.78       -1.72      -1.60     Beat    7.2
 Mar. 31 2022  -1.39       -1.42      -2.00     Missed  -40.8​
 Dec. 31 2021  -1.50       -1.54      -3.90     Missed  -153.2
 ​​Sep.        -1.34       -1.36      -1.40     Missed  -2.9
 30 2021                                                
 Jun. 30 2021  -1.01       -1.04      -1.20     Missed  -15.4​
 Mar. 31 2021  -1.10       -1.05      -0.90     Beat    14.3
 Dec. 31 2020  -0.80       -0.80      -1.70     Missed  -112.5
 This summary was machine generated March 24 at 12:15 GMT.  All
figures in US dollars  unless otherwise stated